C4 Therapeutics(US:CCCC)2021-05-28 18:52Company Overview - C4 Therapeutics is developing targeted protein degradation medicines to transform patient care[7] - The company has a strong balance sheet with $346 million in cash as of March 31, 2021[7] - The TORPEDO platform has the potential to efficiently design highly potent degrader medicines[7] - C4 Therapeutics has three partnerships that expand platform potential, with up to $2 billion in potential milestones[7] Pipeline and Programs - The company expects 4 programs to be in the clinic by the end of 2022[7] - There are 14 additional programs in earlier pre-clinical development[7] - IKZF1/3 degrader CFT7455 is in Phase 1/2 trial, with first clinical data expected in 2022[39, 71] - BRD9 degrader CFT8634 IND submission is expected in the second half of 2021[48] - EGFR degrader CFT8919 IND submission is expected mid-2022, with potential Phase 1/2 trial initiation by the end of 2022[55] Targeted Protein Degradation - Targeted protein degradation has the potential to drug the remaining ~85% of the human proteome and overcome resistance to existing inhibitor medicines[5] - Oncology small molecule therapies generated $63 billion in global revenue in 2018 despite known limitations[5]